The strength of VB’s business model lies in its ability to integrate targeted diagnostic and therapeutic platform applications and exploit the development and commercialization of both traditional and alternative medicine such as cannabinoid-based medicine that include nuclear medicine and therapeutic applications to provide an approach to addressing certain forms of cancer, epilepsy, PTSD and other neurodegenerative disorders using proprietary technology and issued patents (IP).

VB’s methods, development, and replicable and scalable processes through the completion of Phase Zero will demonstrate the effectiveness and scalability for “Big Pharma” companies to execute long-term licensing agreements with VB to enable them to conduct phase I, II, & III human trials and receive FDA approval for global distribution through their own channels